Skip to main content

Common Dreams. Journalism funded by people, not corporations.

There has never been—and never will be—an advertisement on our site except for this one: without readers like you supporting our work, we wouldn't exist.

No corporate influence. No pay-wall. Independent news and opinion 365 days a year that is freely available to all and funded by those who support our mission: To inform. To inspire. To ignite change for the common good.

Our mission is clear. Our model is simple. If you can, please support our Fall Campaign today.

Support Our Work -- No corporate influence. No pay-wall. Independent news funded by those who support our mission: To inform. To inspire. To ignite change for the common good. Please support our Fall Campaign today.

A nurse holds a vial of the Moderna vaccine

A nurse shows a vial of the Moderna Covid-19 vaccine in Bogota, Colombia on August 3, 2021. (Photo: Daniel Romero/Long Visual Press/Universal Images Group via Getty Images)

Moderna Founders Make Forbes 400 Richest List as Company Refuses to Share Vaccine With Poor

"A few people have made billions off the Moderna vaccine, a lifesaving technology produced almost entirely with taxpayer funds."

Jake Johnson

Two of Moderna's founders landed on this year's Forbes 400 list of the richest people in the U.S. as the Massachusetts-based pharmaceutical giant continues to rake in major profits from its coronavirus vaccine—and resists calls to share the recipe with the rest of the world.

Moderna chairman and co-founder Noubar Afeyan, board member and co-founder Robert Langer, and early investor Timothy Springer each appeared on the Forbes list for the first time.

As the Washington Post reported Wednesday, all three of the newly minted billionaires "own a stake in the biotech company, which saw its shares soar last year and which—along with U.S. drug giant Pfizer and German partner BioNTech—logged billions of dollars in vaccine sales as the virus spread."

For months, Moderna—the maker of one of the two available mRNA vaccines—has come under fire from public health campaigners for spurning technology transfer efforts that would help boost global vaccine supply and equalize distribution, which has thus far been dramatically skewed toward rich countries.

To date, just 2.3% of people in low-income countries have received at least one coronavirus vaccine dose.

Critics have repeatedly pointed out that Moderna's coronavirus vaccine development program was 100% funded by U.S. taxpayers. Experts have also stressed that the U.S. government owns a patent covering key spike-protein technology used in Moderna's vaccine, meaning the Biden administration has leverage to force the company to share its recipe and manufacturing know-how.

Reluctant to use such leverage, President Joe Biden has privately urged Moderna to license its technology to qualified manufacturers in low-income countries—but the company has declined to cooperate.

"A few people have made billions off the Moderna vaccine, a lifesaving technology produced almost entirely with taxpayer funds," the Citizens Trade Campaign, a coalition of U.S.-based labor and environmental organizations, said Wednesday. "Meanwhile, the company refuses requests to share the vaccine recipe so more doses can be made in low-income countries."

Thus far, Moderna has sold the overwhelming majority of its vaccine supply to rich countries such as the United States, where more than 150 million of the company's mRNA shots have been administered.

In a report released last month, Amnesty International noted that Moderna "has not yet delivered a single vaccine dose to a low-income country, has provided just 12% of its vaccines to lower-middle-income countries, and will not deliver the vast majority of its orders for COVAX until 2022."

"Higher prices mean it is set to earn over $47 billion in revenues by the end of 2022," Amnesty estimated.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

'Progressives Won't Leave Working Families Behind': Jayapal Stands Ground Against Pelosi-Biden

"We've been clear since the spring: the infrastructure bill and the Build Back Better Act pass together—and that hasn't changed."

Brett Wilkins ·


'Too Bad We Can't Tax Egos': Elon Musk Blasted for Attack on Billionaire Tax

"This country made him rich," said one critic. "He owes us."

Julia Conley ·


'Hold the Line': Progressives Push to Block Vote on Weaker Bill Without Final Text of Build Back Better

"By holding firm on keeping the Build Back Better Act and the Bipartisan Infrastructure Bill firmly linked, progressives are giving their colleagues in the Senate the space and the leverage to negotiate the strongest package possible."

Common Dreams staff ·


Will They Lie or Finally Come Clean?: Watch Fossil Fuel CEOs Testify at Historic Hearing

"Will these executives own up to their misinformation, or keep trying to hide behind lies and spin?"

Andrea Germanos ·


'Pelosi Absolutely Destroyed' Tax on Billionaires, Says Democratic Insider

"The idea that Manchin is to blame for killing the billionaires' tax is too convenient," argued a journalist who spoke with party aides about the moribund proposal.

Kenny Stancil ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo